Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors
NCT06139783 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32
Last updated 2025-06-25
Summary
Patients will be recruited in the 4 participating sites and will sign the informed consent If they agree to participate. It is planned to include 32 patients with ovarian cancer on maintenance PARPi after response to first-line platinum-based chemotherapy in the study.
Patients included in the study will follow an online physical exercise program supervised by a physical exercise specialist in which they will perform up to 300 minutes of moderate-intensity aerobic exercise or up to 150 minutes of vigorous aerobic exercise and 2 strength sessions per week for 12 weeks (following World Health Organization (WHO) recommendations for cancer survivors).
Conditions
Interventions
- PROCEDURE
-
Exercise and dietary recommendations
Online physical exercise program and online nutritional assessment with personalized health and dietary recommendations
Sponsors & Collaborators
-
Apices Soluciones S.L.
collaborator INDUSTRY -
Oncare Madrid
lead OTHER
Principal Investigators
-
Alfonso Cortés, MD · Hospital Universitario Ramón y Cajal
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-31
- Primary Completion
- 2027-01-31
- Completion
- 2027-01-31
Countries
- Spain
Study Locations
More Related Trials
-
An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients
NCT02878980 ·Status: WITHDRAWN ·Phase: NA
-
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00028743 ·Status: COMPLETED ·Phase: PHASE3
-
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
NCT01372787 ·Status: UNKNOWN
-
Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer
NCT04830709 ·Status: RECRUITING
-
Systems Oncology Approach to Optimize Ovarian Cancer Treatment
NCT06117384 ·Status: RECRUITING
-
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
NCT03690739 ·Status: TERMINATED ·Phase: PHASE3
-
Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
NCT04152941 ·Status: COMPLETED
-
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
NCT06121401 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer
NCT02125513 ·Status: UNKNOWN ·Phase: PHASE2
-
Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer
NCT02082470 ·Status: COMPLETED ·Phase: NA
-
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
NCT04724031 ·Status: UNKNOWN
-
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
NCT03740165 ·Status: COMPLETED ·Phase: PHASE3
-
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
NCT01081262 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
NCT02004093 ·Status: COMPLETED ·Phase: PHASE2
-
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
NCT06710548 ·Status: RECRUITING ·Phase: NA
-
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
NCT05080556 ·Status: RECRUITING ·Phase: PHASE2
-
An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer
NCT01266954 ·Status: COMPLETED ·Phase: PHASE1
-
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
NCT01468909 ·Status: COMPLETED ·Phase: PHASE2
-
Optimize the Support of Patients in Pelvic Onco-gynecology Through Adapted Support Care in the Post-cancer Period. AFTERGYN Pilot Phase
NCT05731661 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
First Line Ovarian Cancer Treatment - Cohort Study
NCT01832415 ·Status: COMPLETED
-
Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer
NCT02312661 ·Status: COMPLETED ·Phase: PHASE1
-
The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer
NCT01556841 ·Status: COMPLETED ·Phase: PHASE2
-
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
NCT01422265 ·Status: COMPLETED
-
Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients
NCT06070285 ·Status: NOT_YET_RECRUITING
-
Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer
NCT02681432 ·Status: UNKNOWN ·Phase: PHASE3